A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC

A Phase 1/2a Study to Evaluate the Safety, Tolerability, Whole-Body Distribution, and Preliminary Clinical Activity of 161Tb-RAD402, a Radiolabeled Anti-KLK3 Monoclonal Antibody Targeting Free Prostate-Specific Antigen, in Participants with Castration-Resistant Prostate Cancer (CRPC).

Trial Details

NCT ID
NCT07259213
Phase
PHASE1 / PHASE2
Sponsor
Radiopharm Theranostics, Ltd
Status
RECRUITING
Cancer Type
Castration-Resistant (CRPC) Prostate Cancer
Interventions
  • 161Tb RAD402
Locations (sample)
  • Wollongong, New South Wales, Australia|-34.424,150.89345
  • Nedlands, Western Australia, Australia|-31.98184,115.8073

Key Eligibility Criteria

  • Willing and able to provide informed consent prior to start of any study procedures and assessments and must be willing to comply with all study pr…
  • Male participants ≥ 18 years of age.
  • Participants with a documented history of histopathologically confirmed locally advanced or metastatic CRPC defined as follows:
  • Progressive CRPC defined as castrate levels of testosterone and progressing by at least one of the following criteria:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Castration-Resistant (CRPC) Prostate Cancer Trials on Trialify →